Perceptive Advisors LLC Decreases Stake in ADMA Biologics Inc $ADMA

Perceptive Advisors LLC reduced its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 47.1% during the first quarter, HoldingsChannel reports. The firm owned 467,233 shares of the biotechnology company’s stock after selling 416,235 shares during the period. Perceptive Advisors LLC’s holdings in ADMA Biologics were worth $4,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. State Street Corp increased its holdings in ADMA Biologics by 0.3% in the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after buying an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP lifted its stake in ADMA Biologics by 27.0% during the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after acquiring an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP boosted its holdings in shares of ADMA Biologics by 36.9% during the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after acquiring an additional 1,886,105 shares during the last quarter. Capital Research Global Investors grew its stake in shares of ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after acquiring an additional 3,383,559 shares during the period. Finally, Nuveen LLC raised its holdings in shares of ADMA Biologics by 3.5% during the fourth quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after purchasing an additional 202,245 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other ADMA Biologics news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.90% of the company’s stock.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Negative Sentiment: The lawsuit alleges that ADMA and certain senior executives made materially misleading statements about the company’s financial condition, revenue recognition, inventory distribution and business practices. The allegations have not been proven in court. Hagens Berman ADMA class action notice
• Negative Sentiment: Additional notices cite more specific claims, including alleged channel stuffing and an undisclosed related-party distributor operating from ADMA’s headquarters. If substantiated, such claims could undermine confidence in reported sales quality and corporate governance. SueWallSt ADMA shareholder alert
• Neutral Sentiment: The reported class period runs from August 9, 2024, through March 25, 2026. Investors who acquired ADMA securities during that period have until August 10, 2026 to apply to serve as lead plaintiff; the deadline is a procedural step and does not determine the merits of the case. Kahn Swick and Foti deadline notice
• Negative Sentiment: Multiple firms—including Lowey Dannenberg, Faruqi & Faruqi, Robbins Geller, Rosen and others—are soliciting affected investors or investigating potential federal securities-law violations. The volume of notices may amplify reputational concerns and litigation overhang even though most releases repeat the same underlying allegations. Lowey Dannenberg ADMA investigation

ADMA Biologics Trading Down 2.4%

ADMA Biologics stock opened at $8.46 on Friday. ADMA Biologics Inc has a 52-week low of $7.21 and a 52-week high of $20.46. The company has a market cap of $1.96 billion, a P/E ratio of 12.44 and a beta of 0.73. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The business has a 50-day simple moving average of $8.50 and a two-hundred day simple moving average of $11.60.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. The firm had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.11 EPS. Analysts predict that ADMA Biologics Inc will post 0.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Canaccord Genuity Group decreased their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.